Brought to you by 
Sosei enlists marketing partner for Atrix's Eligard
14 Jan 2004
Executive Summary
Sosei Co. Ltd., which a year ago licensed exclusive Japanese rights to develop and market Atrix Laboratories' Eligard for treating advanced prostate cancer, announced it will be co-promoting the drug with Nippon Organon KK, the Japanese presence of Akzo Nobel's Organon group.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sosei enlists marketing partner for Atrix's Eligard
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice